Clear diagnostic insights help patients evaluate how physical injury, infections, cancer treatments, and medications cause primary testicular failure and low testosterone levels.
Medical Disclaimer: The information provided in this article is for educational and informational purposes only. It is not intended as personal medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider regarding any medical condition, laboratory interpretation, or treatment plan.
Testicular causes of low testosterone refer to conditions where hormone deficiency originates directly within the testes themselves, rather than from signaling failures in the brain. This state is clinically known as primary hypogonadism. It occurs when the specialized cells responsible for androgen production cannot generate adequate testosterone despite receiving clear biochemical signals to do so.
Understanding testicular dysfunction requires separating it from secondary hormonal disruptions. While pituitary and hypothalamic issues involve a lack of upstream signaling, primary testicular failure involves tissue damage, cell loss, or structural disruption within the gonads. This guide provides an in-depth review of the mechanisms behind testicular injury, infectious diseases, surgical interventions, and cancer treatments. It also examines how clinicians evaluate these conditions using precise diagnostic biomarkers.
Primary hypogonadism represents an intrinsic failure of the testes to carry out their normal endocrine responsibilities. Under healthy physiological conditions, hormone production relies on the hypothalamic-pituitary-gonadal axis. The hypothalamus releases gonadotropin-releasing hormone, which prompts the pituitary gland to secrete luteinizing hormone and follicle-stimulating hormone. Luteinizing hormone travels through the bloodstream to bind with receptors on Leydig cells, triggering the enzymatic conversion of cholesterol into testosterone.
When testicular tissue experiences physical injury, ischemic damage, or cellular toxicity, Leydig cells lose their capacity to synthesize testosterone. The pituitary gland senses this deficit through negative feedback mechanisms. In response, it increases the release of luteinizing hormone into the circulation. This creates the classic biochemical hallmark of primary testicular failure: low circulating testosterone paired with elevated luteinizing hormone levels.
It is critical to distinguish between the endocrine and exocrine functions of the testes. Leydig cells occupy the interstitial space between the seminiferous tubules and manage testosterone production. In contrast, Sertoli cells and the germinal epithelium line the seminiferous tubules to direct sperm development under the influence of follicle-stimulating hormone. Because these cell populations have different biological sensitivities, testicular damage does not always affect both systems equally.
A patient may experience severe disruption of the seminiferous tubules resulting in impaired fertility while maintaining intact Leydig cell function and normal testosterone levels. Conversely, extensive damage to the interstitial tissue can suppress androgen synthesis while leaving some degree of sperm production intact. Recognizing this functional division helps individuals better understand why testosterone fundamentals and hormonal function involve distinct diagnostic tracks for fertility and hormone production.
Physical damage to the scrotum can impair hormonal function through mechanical crushing, disruption of the testicular blood supply, or permanent loss of viable tissue. The severity of the outcome depends on whether the injury affects one or both testes, the duration of any blood flow restriction, and the success of medical or surgical interventions.
Testicular torsion is a time-sensitive urological emergency that occurs when the spermatic cord twists, cutting off venous return and arterial blood flow to the testis. Without rapid surgical detorsion, prolonged ischemia leads to tissue infarction and cellular death. Research shows that torsion can lead to long-term testicular atrophy, even after successful surgical detorsion and fixation. In one clinical review of patients with salvageable testes, clinical evidence of atrophy occurred in half of the subjects at 14 months of follow-up, defined as a testicular volume loss greater than 50 percent compared to the uninjured side.
Despite the frequency of post-torsion atrophy, the overall endocrine impact across patient populations varies. A comprehensive review of torsion outcomes noted that most clinical studies found overall endocrine parameters remained largely unaffected over time. The uninjured contralateral testis frequently increases its output to compensate for the damaged tissue. However, subtle hormonal shifts can still occur, meaning that torsion does not automatically lead to lifelong androgen deficiency for every individual.
When torsion or severe mechanical trauma necessitates an orchiectomy, the reduction in total testicular mass can create measurable shifts in endocrine markers. A follow-up study evaluating long-term outcomes found that patients who underwent unilateral orchiectomy for torsion exhibited higher follicle-stimulating hormone levels and lower total and free testosterone concentrations compared to patients whose testes were surgically preserved. While bilateral orchiectomy causes an immediate and complete cessation of testicular androgen production, unilateral loss requires individualized clinical monitoring to verify whether the remaining gonad maintains normal systemic hormone concentrations.
Infectious and inflammatory conditions can directly compromise testicular tissue through cellular destruction, localized swelling, and microvascular thrombosis. Orchitis, which refers to inflammation of one or both testes, is recognized in established clinical guidelines as an acquired cause of primary hypogonadism. While bacterial infections often spread from the urinary tract or epididymis, viral pathogens represent a major cause of direct gonadal damage.
Mumps orchitis is the most extensively documented viral infection affecting testicular endocrine and reproductive function. When mumps occurs in post-pubertal males, testicular involvement develops in a significant portion of cases. The virus invades the parenchymal tissue of the testes, creating acute interstitial edema, lymphocytic infiltration, and increased pressure within the rigid tunica albuginea. This acute inflammatory environment can damage the germinal epithelium and impair the enzymatic processes necessary for steroidogenesis within Leydig cells.
Long-term follow-up research indicates that mumps orchitis can lead to chronic testicular atrophy and progressive Leydig cell loss. In severe bilateral presentations, the destruction of interstitial architecture can result in persistent reductions in circulating testosterone and compensatory elevations in pituitary gonadotropins. While some individuals recover normal Leydig cell activity after the acute infection resolves, others experience lasting deficits in both hormone synthesis and sperm production.
Non-mumps viral infections and non-specific inflammatory orchitis can also impair testicular function, though published evidence for permanent androgen deficiency is less robust. Acute inflammation often produces transient drops in testosterone due to systemic inflammatory cytokines and local vascular stress. Clinicians typically avoid diagnosing permanent primary hypogonadism during or immediately following an acute infectious episode, preferring to re-evaluate hormonal parameters after the tissue has had adequate time to heal.
Testicular cancer and its associated treatments represent one of the most thoroughly studied areas of acquired primary hypogonadism. Testicular germ cell tumors frequently develop in young adult men, a demographic where long-term survivorship and quality of life are central clinical considerations. Both the underlying disease process and the multimodal treatments required for cure can negatively affect endocrine capacity.
The standard initial intervention for suspected testicular cancer is a radical inguinal orchiectomy to remove the affected testis. Unilateral orchiectomy immediately reduces total functional Leydig cell mass by approximately half. In many patients, the remaining solitary testis compensates by increasing its hormone production under the stimulation of slightly higher luteinizing hormone levels. However, if the remaining testis possesses underlying pre-existing developmental abnormalities, it may struggle to maintain normal baseline testosterone levels over the long term.
Adjuvant therapies, including cytotoxic chemotherapy and radiotherapy, introduce additional risks to gonadal health. Leydig cells are generally more resilient to cellular injury than the rapidly dividing germ cells responsible for spermatogenesis. However, they remain vulnerable to high cumulative doses of platinum-based chemotherapy regimens and direct ionizing radiation. Chemotherapy can induce direct cytotoxic damage to Leydig cell DNA, impair mitochondrial function, and accelerate cellular senescence within the interstitial space.
Ionizing radiation disrupts testicular tissue in a dose-dependent manner. Clinical literature indicates that Leydig cell function can become impaired when direct or scattered radiation doses exceed 20 to 30 Gray. While lower radiation doses primarily damage the germinal epithelium and cause infertility, higher cumulative exposures often suppress androgen synthesis, with historical reviews indicating that 15 to 25 percent of heavily irradiated patients eventually require hormone replacement therapy. Modern radiotherapy protocols use precise shielding to minimize scatter to the remaining gonad, yet long-term surveillance remains necessary.
Clinical studies illustrate how combined oncological modalities elevate the risk of hypogonadism compared to surgery alone:
These statistics demonstrate that oncological treatments can exert progressive, late-onset effects on endocrine capacity. Cancer survivorship guidelines from organizations such as the Cancer Council Australia emphasize that testicular hormone deficits may not manifest immediately following treatment, but can instead emerge many years or even decades later as normal age-related declines interact with previously damaged testicular reserve. Men with a history of cancer treatment can read more within our low testosterone signs, causes and risk factors section to understand these distinct longitudinal patterns.
Beyond physical injury, infection, and oncology treatments, several other acquired conditions and pharmacological exposures can impair testicular steroidogenesis. Established clinical frameworks, such as the European Association of Urology guidelines, categorize these factors as direct acquired causes of primary hypogonadism.
Autoimmune testicular failure occurs when the immune system generates autoantibodies directed against Leydig cell surface antigens or steroidogenic enzymes. This condition may present as an isolated disorder or as part of a broader autoimmune polyglandular syndrome. The resulting lymphocytic infiltration leads to chronic interstitial inflammation, progressive fibrosis, and a gradual reduction in circulating testosterone concentrations. Because autoimmune destruction progresses slowly, it can be challenging to identify without specialized immunological and endocrine testing.
Certain pharmacological agents interfere directly with the biochemical pathways responsible for androgen production within the testes. Key categories include:
It is vital to distinguish direct testicular toxicants from medications that suppress testosterone via central feedback pathways. For example, the administration of exogenous testosterone or anabolic-androgenic steroids suppresses the hypothalamic-pituitary axis. This halts the release of luteinizing hormone and follicle-stimulating hormone. Without pituitary stimulation, the testes cease endogenous testosterone production and spermatogenesis, leading to secondary testicular atrophy. While this secondary suppression profoundly alters gonadal size and output, it does not represent intrinsic structural damage to the Leydig cells themselves.
Accurately diagnosing low testosterone requires a structured, multi-step clinical evaluation. Professional medical organizations, including the Endocrine Society, emphasize that testosterone deficiency cannot be diagnosed from symptoms alone or from a single blood test. Because hormone levels naturally fluctuate and can be temporarily suppressed by acute illness, stress, or poor sleep, clinical confirmation requires a rigorous testing and biomarkers protocol.
The diagnostic process begins with confirming genuinely low circulating androgen levels. Guidelines recommend measuring total testosterone from a fasting blood sample collected in the early morning, typically between 7:00 AM and 10:00 AM, when physiological concentrations reach their peak. If the initial result falls below the reference range, the clinician must repeat the test on a separate morning under identical fasting conditions. If total testosterone is borderline, or if the patient has conditions that alter sex hormone-binding globulin, calculating free testosterone provides a clearer picture of biologically active hormone availability.
Once persistent androgen deficiency is confirmed, the clinician must differentiate between primary testicular failure and secondary hypothalamic-pituitary dysfunction. This is achieved by measuring gonadotropins:
Clinicians also monitor for a state known as compensated hypogonadism. In this scenario, circulating total and free testosterone concentrations remain within normal reference limits, but luteinizing hormone is chronically elevated. This pattern indicates that the pituitary gland is working harder than normal to maintain baseline steroidogenesis, signaling reduced functional testicular reserve. While compensated hypogonadism does not always cause noticeable symptoms or require immediate medical therapy, identifying it allows clinicians to monitor the patient for future transitions into overt primary failure.
When reviewing medical research on testicular causes of low testosterone, it is important to distinguish between robust clinical guidelines and observational or cohort-level data. Clinical consensus statements from bodies such as the Endocrine Society and the European Association of Urology provide the highest level of diagnostic guidance. These guidelines firmly establish that primary hypogonadism is characterized by low serum testosterone accompanied by hypergonadotropic signaling.
The evidence linking major structural disruptions to androgen deficiency is clear and uncontroversial. Bilateral surgical orchiectomy results in complete primary hypogonadism across all patient populations. Similarly, high-dose gonadal irradiation and extensive direct testicular trauma consistently produce measurable reductions in Leydig cell mass.
However, the evidence regarding other acquired conditions is more nuanced:
Recognizing these distinctions ensures that patients view historical medical events as reasons for appropriate clinical screening rather than as guaranteed causes of permanent hormone failure. Those interested in broader research methodologies can explore our testosterone testing and biomarkers guides for further details on how clinical studies establish hormone reference intervals.
Navigating potential testicular causes of low testosterone requires open, informed communication with a primary care physician, urologist, or endocrinologist. If you have a personal history involving scrotal trauma, torsion, severe infection, or oncological treatment, sharing this context helps your provider determine the most effective diagnostic strategy.
Consider discussing the following evidence-informed questions during your clinical consultation:
These questions help establish an objective, collaborative diagnostic process. They ensure that decisions are based on confirmed laboratory evidence and comprehensive physical assessments rather than assumptions. For individuals considering long-term clinical management strategies, our overview of TRT, treatment and emerging testosterone science provides further context on standard therapeutic boundaries.
No. In many cases, a single healthy testis can enlarge and increase its steroidogenic output to compensate for the missing tissue. The pituitary gland increases luteinizing hormone release slightly, prompting the remaining Leydig cells to produce enough testosterone to maintain normal circulating levels. However, if the remaining testis has underlying cellular damage or if its blood supply was compromised, it may not fully compensate. Routine clinical evaluation with morning hormone testing is the only way to determine whether a solitary testis is maintaining sufficient output.
Mumps orchitis can cause acute structural damage to the seminiferous tubules and interstitial Leydig cells. In severe cases, this leads to lasting testicular atrophy and a reduced population of hormone-producing cells. While some men experience permanent deficits immediately following the infection, others maintain adequate compensation until the normal aging process further reduces Leydig cell numbers. If you had mumps orchitis during or after puberty, discussing this history with your doctor can help determine if hormone testing is warranted.
The primary difference lies in the anatomical origin of the dysfunction. In primary hypogonadism, the problem resides within the testes; the Leydig cells cannot produce adequate testosterone despite receiving strong signals from the brain, resulting in low testosterone and elevated luteinizing hormone. In secondary hypogonadism, the issue stems from the hypothalamus or pituitary gland; the brain fails to produce sufficient signaling hormones, resulting in low testosterone alongside low or inappropriately normal luteinizing hormone. Distinguishing between these two conditions requires measuring gonadotropins alongside testosterone.
Not necessarily, although the two functions are frequently linked. Testosterone production by Leydig cells and sperm production within the seminiferous tubules represent two distinct physiological systems within the testes. Severe physical trauma or toxic exposures can damage both systems simultaneously, leading to concurrent hypogonadism and infertility. However, some men experience selective damage that impairs one system more than the other. A formal semen analysis alongside comprehensive hormone testing is required to accurately evaluate both reproductive and endocrine health.
Testostra explains testosterone biology, testing, symptoms, lifestyle factors and TRT with careful sourcing and clear clinical limits.
Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra
